Cargando…
Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis
BACKGROUND/AIMS: Treatment of refractory ulcerative colitis (UC) is a clinical challenge, and after biological therapy, monitoring clinical and endoscopic responses is fundamental. We aimed to investigate and compare the predictive power of different noninvasive parameters for clinical remission and...
Autores principales: | Hassan, Elham A., Ramadan, Haidi K., Ismael, Ali A., Mohamed, Khaled F., El-Attar, Madiha M., Alhelali, Ihab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539678/ https://www.ncbi.nlm.nih.gov/pubmed/28721978 http://dx.doi.org/10.4103/sjg.SJG_599_16 |
Ejemplares similares
-
Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019) -
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009) -
Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008) -
Infliximab Induction Strategies in Corticosteroid-Refractory Acute Severe Ulcerative Colitis: A Case Series and Literature Review
por: Antunes, Pedro Bernardes, et al.
Publicado: (2022) -
Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)